Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Sipuleucel-T – A Model for Immunotherapy Trial Development
Introduction Among five new therapies for patients with metastatic castration-resistant prostate cancer, sipuleucel-T (Provenge ® ) stands out as the first immunotherapy approved by the FDA for asymptomatic or minimally symptomatic castrate metastatic prostate cancer with the added benefit of…